Latest Posts


May 24

Partex and Singapore’s Experimental Drug Development Centre collaborate to bring forward an innovative approach for early drug discovery and development

Frankfurt, Germany, 3rd June 2024, 9am CET Partex, a leading provider of AI-driven solutions in the pharmaceutical industry, is thrilled...
Read More


Apr 24

Partex Partners with Lupin to Revolutionize Drug Discovery through AI-Driven Asset Search and Evaluation

Frankfurt, Germany, 23 April 2024 – Partex, a leading provider of AI-driven solutions in the pharmaceutical industry, is thrilled to...
Read More

Innoplexus wins Horizon Interactive Gold Award for Curia App

Read More
Try Ontosight® For Free

Innoplexus Featured in DataQuest

Innoplexus launches iPlexus to transform decision support in the Life Sciences Industry

Innoplexus, the technology and product development company focused on AI and advanced analytics, announced the launch of its product iPlexus, an end to end platform for Life Sciences which leverages artificial intelligence to generate continuous intelligence and insights across discovery, clinical development, regulatory and commercial stages of drug development, spanning all major therapeutic areas and indications. iPlexus facilitates better ways of discovering, exploring and analyzing biomedical research.

The platform has crawled, curated and indexed hundreds of terabytes of scientific data across hundreds of clinical trial databases, biological databases, major patent offices, congresses, theses, forums, regulatory bodies and much more. Users get quick, crisp and summarized snapshots of the current landscape in any given context, be it important deals and mergers, fast-tracked clinical trials etc, helping them make informed and data-backed decisions. In the drug development process, traditionally, there was a lack of a single source of information for reference.

Speaking on the launch, Dr.Gunjan Bharadwaj, Founder and Chairman, Innoplexus, commented, “We are extremely excited to launch iPlexus. Traditionally, both production and consumption of intelligence and insights in enterprises remain predominantly manual. In the current scenario of big data, analytics and machine learning, teams of analysts in companies still curate data manually. These companies then sell it to customers at very high prices. Today, the volume, velocity, variability and veracity of data makes this manual process impossible. Our goal is to make access to insights real-time, comprehensive and cost effective. iPlexus ensures instant availability of insights across deep, dense and diverse data sets for taking informed decisions in key therapeutic areas, while saving time and effort from collecting and updating the same information from different sources manually. The platform makes use of machine learning and AI to generate continuous intelligence. It’s also a mission to democratize data and insights for small and medium organizations which cannot afford traditional offerings”

“iPlexus helps in the better discovery of valuable research available with institutes/labs, small pharma and large pharma organizations, niche biotech companies, academic institutes, various conferences, congresses, societies etc. This research data may not be instantly discoverable as the source of each is different. Information is therefore scattered and is not readily available to a researcher, for consumption. Our platform bridges this gap by collecting, cleaning, categorizing, analyzing and arranging various kinds of information readily for the user, backed by cutting edge tech.”, he added.

iPlexus makes relevant information readily available to a researcher which can be referred to at any point, as per their requirement.

For instance, if a researcher is working on a niche molecule and iPlexus gives him/her an information byte that a close competitor has already got positive results working with a similar molecule, then the researcher can use this information to decide his/her next steps in the research chain. Similarly, if a user is looking for research papers on a specific topic and he/she gets to know about something that is trending within the topic domain, it would be an added advantage.

The original article was published on DataQuest.

Featured News

Strategic partnership announcement: Innoplexus holding company Partex NV is pleased to announce a one-of-its-kind collaboration with Anavex Life science corp. for Artificial Intelligence (AI) enabled drug development and healthcare sales marketing

Strategic partnership announcement: Innoplexus holding company Partex NV is pleased

Exciting News! Anavex Life Sciences and Partex NV Announce Strategic Partnership to Enhance Patient Experience. Anavex Life Sciences Corp. and Partex NV N.V. Group are pleased to announce…